Barclays’s Verve Therapeutics VERV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.39M | Buy |
301,599
+114,631
| +61% | +$1.29M | ﹤0.01% | 1871 |
|
|
2025
Q1 | $855K | Sell |
186,968
-33,763
| -15% | -$154K | ﹤0.01% | 2535 |
|
|
2024
Q4 | $1.24M | Sell |
220,731
-2,188
| -1% | -$12.3K | ﹤0.01% | 2501 |
|
|
2024
Q3 | $1.08M | Buy |
222,919
+129,944
| +140% | +$629K | ﹤0.01% | 2577 |
|
|
2024
Q2 | $454K | Buy |
92,975
+13,318
| +17% | +$65K | ﹤0.01% | 2585 |
|
|
2024
Q1 | $1.06M | Sell |
79,657
-114,971
| -59% | -$1.53M | ﹤0.01% | 2365 |
|
|
2023
Q4 | $2.71M | Buy |
194,628
+50,410
| +35% | +$702K | ﹤0.01% | 1947 |
|
|
2023
Q3 | $1.91M | Buy |
144,218
+22,898
| +19% | +$304K | ﹤0.01% | 1703 |
|
|
2023
Q2 | $2.28M | Buy |
121,320
+12,474
| +11% | +$234K | ﹤0.01% | 1668 |
|
|
2023
Q1 | $1.57M | Sell |
108,846
-93,543
| -46% | -$1.35M | ﹤0.01% | 1811 |
|
|
2022
Q4 | $3.92M | Buy |
202,389
+88,718
| +78% | +$1.72M | ﹤0.01% | 1246 |
|
|
2022
Q3 | $3.91M | Buy |
113,671
+108,815
| +2,241% | +$3.74M | ﹤0.01% | 1240 |
|
|
2022
Q2 | $74K | Sell |
4,856
-20,139
| -81% | -$307K | ﹤0.01% | 3589 |
|
|
2022
Q1 | $571K | Buy |
+24,995
| New | +$571K | ﹤0.01% | 2718 |
|